06-4534. New Animal Drugs; Change of Sponsor; Fomepizole  

  • Start Preamble

    AGENCY:

    Food and Drug Administration, HHS.

    ACTION:

    Final rule.

    SUMMARY:

    The Food and Drug Administration (FDA) is amending the animal drug regulations to reflect a change of sponsor for a new animal drug application (NADA) for fomepizole solution for injection from Orphan Medical, Inc., to Jazz Pharmaceuticals, Inc. The regulations are also being amended to reflect approval of a supplemental NADA to remove a vial of saline diluent from this product.

    DATES:

    This rule is effective May 16, 2006.

    Start Further Info

    FOR FURTHER INFORMATION CONTACT:

    Melanie R. Berson, Center for Veterinary Medicine (HFV-110), Food and Drug Administration, 7500 Standish Pl., Rockville, MD 20855, 301-827-7540, e-mail: melanie.berson@fda.hhs.gov.

    Start Printed Page 28266 End Further Info End Preamble Start Supplemental Information

    SUPPLEMENTARY INFORMATION:

    Orphan Medical, Inc., 13911 Ridgedale Dr., suite 475, Minnetonka, MN 55305, has informed FDA that it has transferred ownership of, and all rights and interest in, NADA 141-075 for ANTIZOL-VET (fomepizole) to Jazz Pharmaceuticals, Inc., 3180 Porter Dr., Palo Alto, CA 94304. A supplement was also filed to NADA 141-075 to remove a vial of saline diluent from this product. The supplemental NADA is approved as of April 18, 2006, and the regulations are amended in 21 CFR 522.1004 to reflect the change of sponsorship, the removal of a vial of saline diluent from the product, and a current format.

    Approval of this supplemental NADA did not require review of additional safety or effectiveness data or information. Therefore, a freedom of information summary is not required.

    Following these changes of sponsorship, Orphan Medical, Inc., is no longer the sponsor of an approved application. Accordingly, 21 CFR 510.600(c) is being amended to remove the entries for Orphan Medical, Inc.

    The agency has determined under 21 CFR 25.33(d)(1) that this action is of a type that does not individually or cumulatively have a significant effect on the human environment. Therefore, neither an environmental assessment nor an environmental impact statement is required.

    This rule does not meet the definition of “rule” in 5 U.S.C. 804(3)(A) because it is a rule of “particular applicability.” Therefore, it is not subject to the congressional review requirements in 5 U.S.C. 801-808.

    Start List of Subjects

    List of Subjects

    21 CFR Part 510

    • Administrative practice and procedure
    • Animal drugs
    • Labeling
    • Reporting and recordkeeping requirements

    21 CFR Part 522

    • Animal drugs
    End List of Subjects Start Amendment Part

    Therefore, under the Federal Food, Drug, and Cosmetic Act and under authority delegated to the Commissioner of Food and Drugs and redelegated to the Center for Veterinary Medicine, 21 CFR parts 510 and 522 are amended as follows:

    End Amendment Part Start Part

    PART 510—NEW ANIMAL DRUGS

    End Part Start Amendment Part

    1. The authority citation for 21 CFR part 510 continues to read as follows:

    End Amendment Part Start Authority

    Authority: 21 U.S.C. 321, 331, 351, 352, 353, 360b, 371, 379e.

    End Authority Start Amendment Part

    2. In § 510.600, in the table in paragraph (c)(1), remove the entry for “Orphan Medical, Inc.” and alphabetically add a new entry for “Jazz Pharmaceuticals, Inc.”; and in the table in paragraph (c)(2) remove the entry for “062161” and numerically add a new entry for “068727” to read as follows:

    End Amendment Part
    Names, addresses, and drug labeler codes of sponsors of approved applications.
    * * * * *

    (c) * * *

    (1) * * *

    Firm name and addressDrug labeler code
    *    *    *    *    *
    Jazz Pharmaceuticals, Inc., 3180 Porter Dr., Palo Alto, CA 94304068727
    *    *    *    *    *

    (2) * * *

    Drug labeler codeFirm name and address
    *    *    *    *    *
    068727Jazz Pharmaceuticals, Inc., 3180 Porter Dr., Palo Alto, CA 94304
    *    *    *    *    *
    Start Part

    PART 522—IMPLANTATION OR INJECTABLE DOSAGE FORM NEW ANIMAL DRUGS

    End Part Start Amendment Part

    3. The authority citation for 21 CFR part 522 continues to read as follows:

    End Amendment Part Start Authority

    Authority: 21 U.S.C. 360b.

    End Authority Start Amendment Part

    4. In § 522.1004, revise paragraphs (a), (b), (c)(1), and (c)(3) to read as follows:

    End Amendment Part
    Fomepizole.

    (a) Specifications. Each vial contains 1.5 grams fomepizole (1.5 milliliter (mL) of 1.0 gram per mL solution).

    (b) Sponsor. See No. 068727 in § 510.600(c) of this chapter.

    (c) * * *

    (1) Amount. 20 milligrams per kilogram (mg/kg) of body weight intravenously initially, followed by 15 mg/kg at 12 and 24 hours, and 5 mg/kg at 36 hours.

    * * * * *

    (3) Limitations. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

    Start Signature

    Dated: May 3, 2006.

    Steven D. Vaughn,

    Director, Office of New Animal Drug Evaluation, Center for Veterinary Medicine.

    End Signature End Supplemental Information

    [FR Doc. 06-4534 Filed 5-15-06; 8:45 am]

    BILLING CODE 4160-01-S

Document Information

Effective Date:
5/16/2006
Published:
05/16/2006
Department:
Food and Drug Administration
Entry Type:
Rule
Action:
Final rule.
Document Number:
06-4534
Dates:
This rule is effective May 16, 2006.
Pages:
28265-28266 (2 pages)
PDF File:
06-4534.pdf
CFR: (2)
21 CFR 510.600
21 CFR 522.1004